follow us:Google+ FacebookLinkedInTwitterRSS Feeds


Merck begins tender offer to acquire Idenix for $4B


Back to Top Comments Email Print

Latest News


Whitehouse Station-based Merck announced Friday that it has initiated its cash tender offer to purchase the outstanding shares of common stock of Idenix Pharmaceuticals Inc.

On June 9, Merck announced its intent to acquire Idenix for $24.50 per share.  The transaction values Idenix at approximately $3.85 billion.

Following the purchase, Idenix will become a wholly owned subsidiary of Merck.

Merck plans to file the terms of the offer Friday with the U.S. Securities and Exchange Commission.

MacKenzie Partners Inc. is the information agent, and Credit Suisse is the financial advisor for Merck. Merck is being legally represented by Hughes Hubbard & Reed LLP.  Centerview Partners is the financial advisor to Idenix, and Idenix is being represented by Sullivan & Cromwell.


Entrepreneur says N.J. is good for business, but has room to improve

Morristown property sold in reported $52 million deal

New Jerseyans paying more than national average for Affordable Care Act plans

Share This Story On:
Emily Bader

Emily Bader

Emily Bader is the copy and web editor at NJBIZ. She is a Brielle, N.J. native and a Rutgers University alum. You can contact her at or @emilybader on Twitter.



Be the first to comment.

Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
     View Comment Policy

Advanced search
Sponsored by
Back to Top